Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation

Individuals using assistive technology may not be able to fully access the information contained in this file. For assistance, please send an e-mail to: ocod@fda.hhs.gov and include 508 Accommodation and the title of the document in the subject line of your e-mail.




COVID-19 Vaccine Implementation: Operational aspects of vaccine distribution and tracking

Janell Routh, MD MHS
Deputy, Implementation Planning Unit
Vaccine Task Force
CDC COVID-19 Response

VRBPAC October 22, 2020






Complex and evolving landscape for COVID-19 vaccine

- One vs. two dose series
- Products not interchangeable
- Vaccine efficacy and adverse event profile in different populations
- Varying cold-chain requirements
- Use in children and pregnant people
- Need for socially distanced vaccination practices
- Communication and education
- Some groups at higher risk for COVID-19 may have concerns with public health and vaccination




Vaccine roll-out is likely to be a phased approach



10/20/20

Multiple components to vaccine implementation



Public health impact relies on rapid, efficient, and high uptake of complete vaccine series, with particular focus on those at increased risk for severe COVID-19 illness



Critical populations to ensure access to COVID-19 vaccine in earlier phases

Critical infrastructure

People at increased risk for severe illness

People at increased risk for COVID-19

People with limited access to vaccinations
























Considerations for Vaccine Administration



- Infection control and social distancing measures
- Storage and handling capacity
- Security
- Ability to administer EUA requirements




Jurisdictions are well-positioned to successfully execute the COVID-19 vaccine program. They know...

- Their populations; their enumerations and where they live
- Where their at-risk populations can be found and who key stakeholders are
- How to reach hard-to-reach populations through established channels
- Where their providers practice and have existing relationships with hospitals
- How to order, track, and report on vaccine administration and adverse events
- How to run vaccination clinics, manage cold chain, store/handle vaccines, and to get vaccine or other product out in an emergency / outbreak situation
- How to execute large-scale vaccination to control and prevent illness



Jurisdictional "Playbook" released September 16, 2020



Centers for Disease Control and Prevention (CDC)

> September 16, 2020 Version 1.0

- Locating Critical Populations
- Vaccination Provider Recruitment, Enrollment and Training
- Vaccination Program Communication
- Vaccine Ordering and Distribution
- Vaccine Storage and Handling (preliminary)
- Vaccine Safety Monitoring (preliminary)
- CDC Dashboards

https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19-Vaccination-Program-Interim Playbook.pdf



CDC Regional Technical Assistance Team to Support Jurisdictional Planning

- Collect and analyze metrics on jurisdictional capacity
- Provide direct TA to individual jurisdictions
- Facilitate cross-jurisdictional regional communication and collaboration
- Train jurisdictions on the use of OWS' Tiberius application and CDC's dashboard
- Review and approve jurisdictional COVID-19 vaccination response plans
- Support phased implementation of jurisdictional vaccination response



To distribute and administer COVID-19 vaccine, we will leverage many partners to ensure success

Leveraging public health expertise and assets from all of USG ...









State

Local

... and contributions from private partners








Distribution

Administration

Guidance & best practices



Timeline for pharmacy partnerships

Limited Doses Available

Large Number of Doses Available

Continued Vaccination, Shift to Routine Strategy

Max

Volume doses available (per month)

Trials only

- Constrained supply
- Highly targeted administration required to achieve coverage in priority populations
- · Likely sufficient supply to meet demand
- Supply increases access
- Broad administration network required, including surge capacity

- · Likely excess supply
- Broad administration network for increased access



LTCF staff (part of HCP recommendation) Phase 1-B

Other essential workers, people at higher risk of severe

COVID-19, people 65

years and older



Increasing access to the general public via pharmacy partnerships with ~16 partners

- pharmacy partners that represent many LTC pharmacies
- Looking to engage with these partners to provide continued access to COVID-19 vaccine in LTCFs through their normal pharmacy channels

10/20/20


Next Steps for Vaccine Implementation

- Work with commercial partners and federal entities who may receive direct allocations to expand access
- Enumerate critical populations who may be prioritized for early vaccine allocation or require special consideration for distribution and access
- Collect vaccine provider agreements and onboard providers to be able to receive and administer vaccine, including providers who serve critical populations
- Ensure state data systems have processes to monitor vaccine distribution, uptake, demand and wastage
- Begin engaging with community stakeholders to address vaccine hesitancy



Rising to the challenge to achieve high coverage with both seasonal influenza and COVID-19 vaccines

Influenza Vaccination Coverage, ≥18 years, by Race/Ethnicity: 2008-09 – 2017-18



- Vaccination coverage of racial and ethnic minorities is consistently lower than that of white populations
- We need novel and more robust strategies to increase uptake of both seasonal influenza vaccine and COVID-19 vaccine, once available



Intentions to Get Vaccinated

- Participants generally open to getting the COVID-19 vaccine <u>eventually</u>
- Many participants hesitant to get the COVID-19 vaccine when <u>first</u> available
- Concerns included:
 - Safety
 - Side effects (both short and long term)
 - Effectiveness
 - Sufficient testing in their group (age, race, ethnicity, underlying conditions)
 - Rapid development process
- Participants wanted more information and/or would "wait and see" before making a final decision (6 months commonly cited as a reasonable time frame)







Vaccinate with Confidence

CDC's Strategy to Reinforce Confidence in COVID-19 Vaccines

Reinforce Trust

Strategy: Regularly share clear and accurate COVID-19 vaccine information and take visible actions to build trust in the vaccine, vaccinator and health system

- ✓ Communicate transparently about the process for approving, making recommendations for, monitoring the safety of, and distributing COVID-19 vaccines
- ✓ Provide regular updates on benefits, safety, and effectiveness, including updates from an independent vaccine safety monitoring group
- ✓ Proactively address and mitigate the spread and harm of misinformation via social media platforms, partners, and trusted messengers

Empower Healthcare Providers

Strategy: Promote confidence among healthcare personnel in their decision to get vaccinated and to recommend vaccination to their patients

- ✓ Engage healthcare personnel often and early to ensure a clear understanding of the vaccine development and approval process, and the benefits of vaccination
- ✓ Ensure healthcare providers can successfully administer COVID-19 vaccine and confidently address vaccine-related questions
- ✓ Support healthcare providers in engaging in empathetic vaccine conversations and sharing tailored vaccine information with

Engage Communities & Individuals

Strategy: Practice equitable and inclusive community engagement

- ✓ Ensure vaccines are available, affordable, and easy-to-get in every community.
- ✓ Amplify reach with national organizations that can impact the health of local communities and create two-way feedback loops with communities about acceptable strategies to promote vaccine uptake
- ✓ Collaborate with trusted messengers in communities of color that are at increased risk for COVID-19 outbreaks and complications

Activities Supporting VwC for COVID-19

INCREASING OWNERSHIP FROM CDC TO JURISDICTION/COMMUNITY LEVEL



VwC Insights

- National level social listening and data collection
- Includes qual, quant, and innovative data collection approaches
- Develop key insights to inform program implementation



VwC Strategy

- Overall CDC vaccine confidence strategy to support uptake of COVID-19 vaccine(s)
- Focused on:
- Reinforcing Trust
- Empowering HCPs
- Engaging Communities & Individuals
- Communications materials development to support vaccine confidence promotion



VwC Rapid Community Assessment Guide

- Retooling draft guide to diagnose undervaccination in specific populations from RI to COVID-19 vaccines
- Focus on understanding equity-related issues, participatory design and intervention development in a less-than-3-day format




VwC Support to Jurisdictions

 Connecting to jurisdictions who would like "confidence consults" and support on designing data collecting tools or interpreting data related to vaccine confidence

CDC Vaccine Web Content


- New content going live at https://www.cdc.gov/coronavirus/2019ncov/vaccines/index.html https://www.cdc.gov/coronavirus/2019ncov/hcp/vaccination.html
- New ACIP webpage that describes ACIP and its recommendation process (general, not COVID-19 specific) https://www.cdc.gov/vaccines/acip/committee/role-vaccine-recommendations.html



Thank you

For more information, contact CDC 1-800-CDC-INFO (232-4636)

TTY: 1-888-232-6348 www.cdc.gov



The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

